Dropping two drug candidates puts Genmab in a better position, says CEO
![CEO of Genmab Jan van de Winkel | Photo: PR/Genmab](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13453350.ece/ALTERNATES/schema-16_9/doc7icqvk78dhdtalei2fh.jpg)
It isn't every day that biotech company Genmab has to abandon a drug under development.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.